China/Asia TMT

Shawn Yang

China growth and global non-US Internet equities

Blue Lotus Research Institute

Blue Lotus Research is a Hong Kong Type 4 Licensed investment advisory firm focusing on Chinese growth equities and global non-US Internet equities

Thematic (Sector/Industry)

<ul>
<li>XPEV: Xpeng and Volkswagen cooperation updates, per the analyst call with IR team (/)</li>
<li>3690.HK: NDRC adds guidelines for restoring consumption of catering and tourism (+)</li>
<li>241HK/ 6618HK：Central Discipline Committee launched crackdown on healthcare corruption (-)</li>
</ul>


XPEV: Xpeng and Volkswagen cooperation updates, per the analyst call with IR team (/)
3690.HK: NDRC adds guidelines for restoring consumption of catering and tourism (+)
241HK/ 6618HK：Central Discipline Committee launched crackdown on healthcare corruption (-)


China TMT Update-XPEV/3690HK/241HK/6618HK-Volkswagen Cooperation;Crackdown on Healthcare Corruption

HK/China Healthcare Analyst (ex-Fosun Pharma)

Xinyao (Criss) Wang

<ul>
<li>China's retail pharmacy market has entered a new era of integration as the industry growth is slowing down. After JD Health/Alibaba Health enter this industry, the game rule changes. </li>
<li>In the short term, the offline chain pharmacies, JD Health, Alibaba Health, etc. would still have the opportunity to carve up market share under the trend of prescription outflow.</li>
<li>In the long term, it depends on who're the first to establish new omni-channel retail scenarios, because the "new retail" model would comprehensively surpass traditional model from cost to experience.</li>
</ul>


China's retail pharmacy market has entered a new era of integration as the industry growth is slowing down. After JD Health/Alibaba Health enter this industry, the game rule changes. 
In the short term, the offline chain pharmacies, JD Health, Alibaba Health, etc. would still have the opportunity to carve up market share under the trend of prescription outflow.
In the long term, it depends on who're the first to establish new omni-channel retail scenarios, because the "new retail" model would comprehensively surpass traditional model from cost to experience.


China Retail Pharmacy Industry - New Game Rule, New Challenges, New Outlook

<ul>
<li>JD:JD is reported to launch “RMB10bn subsidy” channel in March(-)</li>
<li>241HK/6618HK:Shanxi stops allowing first medical consultation to be online, other provinces may follow suit(-)</li>
<li>1024HK:Kwai recruitment releases performance of serial New Spring Recruit Event（+）</li>
</ul>


JD:JD is reported to launch “RMB10bn subsidy” channel in March(-)
241HK/6618HK:Shanxi stops allowing first medical consultation to be online, other provinces may follow suit(-)
1024HK:Kwai recruitment releases performance of serial New Spring Recruit Event（+）


China TMT Update(Feb.20): JD.US, 241HK, 6618HK, 1024HK - JD Is Reported to Launch “RMB10bn Subsidy”

Asia Pac ECM and Index Rebal, Shenton Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

Shenton Research

Shenton Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Quantitative Analysis

<ul>
<li>We analyzed the latest HK SFC report for aggregate short position as of Jul 31st.</li>
<li>Top short increases and decreases were tabulated for one week and four week period.</li>
<li>We highlight short changes in CCB, Tencent, Alibaba, China Mobile, Yofc, Smic, Zijin Gold Intl.</li>
</ul>


We analyzed the latest HK SFC report for aggregate short position as of Jul 31st.
Top short increases and decreases were tabulated for one week and four week period.
We highlight short changes in CCB, Tencent, Alibaba, China Mobile, Yofc, Smic, Zijin Gold Intl.


HK Short Interest Weekly: CCB, Tencent, Alibaba, China Mobile, Yofc, Smic, Zijin Gold Intl

<ul>
<li>China's relaxation of COVID-19 control measures is much faster than expected. Due to rising infection rate and mortality rate, China would bear some pressure in the short term. </li>
<li>We analyzed the direct impacts due to COVID policy shift and related investment opportunities. The hardest time of three-year COVID-19 has passed.The playbook of the pandemic is about to end.</li>
<li>With the new leadership taking office, China will be more committed to economic growth after the Two Sessions. Starting from 2023H2, China could formulate independent financial/monetary policies. China will change. </li>
</ul>


China's relaxation of COVID-19 control measures is much faster than expected. Due to rising infection rate and mortality rate, China would bear some pressure in the short term. 
We analyzed the direct impacts due to COVID policy shift and related investment opportunities. The hardest time of three-year COVID-19 has passed.The playbook of the pandemic is about to end.
With the new leadership taking office, China will be more committed to economic growth after the Two Sessions. Starting from 2023H2, China could formulate independent financial/monetary policies. China will change. 


China Makes U-Turn on COVID Policy - Here Are the Direct Impacts and Investment Opportunities

Hong Kong

Alibaba Health is the flagship healthcare platform of Alibaba Group, providing digital health services and resources. It operates pharmaceutical direct sales, an e-commerce platform for medications and health products, and offers healthcare and digital services including telemedicine consultations. The company is headquartered in Beijing, China, and was founded in 1998.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Alibaba Health (241 HK)

China TMT Update-XPEV/3690HK/241HK/6618HK-Volkswagen Cooperation;Crackdown on Healthcare Corruption

XPEV: Xpeng and Volkswagen cooperation updates(/);3690.HK: NDRC adds guidelines for restoring consumption(+);241HK/6618HK：Central Discipline...

Blue Lotus Research Institute

China Retail Pharmacy Industry - New Game Rule, New Challenges, New Outlook

China's retail pharmacy market has entered a new era with new game rule.As industry growth is slowing down, which companies are the first to...

Xinyao (Criss) Wang

China TMT Update(Feb.20): JD.US, 241HK, 6618HK, 1024HK - JD Is Reported to Launch “RMB10bn Subsidy”

JD is reported to launch “RMB10bn subsidy” channel in March; Shanxi stops allowing first medical consultation to be online; Kwai recruitment...

Blue Lotus Research Institute

HK Short Interest Weekly: CCB, Tencent, Alibaba, China Mobile, Yofc, Smic, Zijin Gold Intl

We analyzed the latest HK SFC report for aggregate short position as of Jul 31st and highlight short interest changes in CCB, Tencent, Alibaba,...

Ke Yan, CFA, FRM

China Makes U-Turn on COVID Policy - Here Are the Direct Impacts and Investment Opportunities

China's U-turn on COVID policy will lead to rising infection/mortality rate.We analyzed the direct impact/investment opportunity. Under new...

Xinyao (Criss) Wang

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)